ICU
SeaStar MedicalยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ICU Profile
Seastar Medical Holding Corp
A medical technology company developing innovative solutions for critically ill patients, including extracorporeal therapies
Healthcare Equipment and Supplies
06/06/2007
03/18/2021
NASDAQ Stock Exchange
19
12-31
Common stock
3513 Brighton Blvd, Suite 410, Denver, CO 80216
--
SeaStar Medical Holding Corp was originally incorporated in Delaware on June 6, 2007 under the name Nephrion, Inc. On August 3, 2007, the company changed its name to CytoPherx Corporation. On June 19, 2019, in a merger transaction, CytoPherx changed its name to SeaStar Medical, a medical technology company focused on the development and commercialization of its lead product candidate, the Selective Cellular Heterotrophic Device (" SCD "), for acute kidney injury (" AKI ") indications in children and adults. SeaStar Medical is currently completing a submission for a Humanitarian Equipment Exemption (" HDE ") for SCD for the treatment of pediatric AKI patients with continuous renal replacement therapy (" CRRT ") and completing the design of a pivotal trial for adult AKI patients with CRRT. SCD received Breakthrough Device Designation from the U.S. Food and Drug Administration (" FDA ") on April 29, 2022 for the treatment of immune modulation disorders in adults aged 18 years and older with AKI.
